Die Behandlung der Myelocytenleukämien mit Dibrommannitol
暂无分享，去创建一个
[1] L. Institóris,et al. Influence of the chemical structure on the biological endency of cytostatic compounds related to dibromomannitol. I. Structure-activity correlations. , 1967, Arzneimittel-Forschung.
[2] G. Mathé,et al. [TRIAL TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH DIBROMOMANNITOL]. , 1964, Nouvelle revue francaise d'hematologie.
[3] S. Eckhardt,et al. [EFFECT OF 1,6-DIBROMO-1,6-D-DIDESOXYMANNITOL (DBM) ON CHRONIC MYELOID LEUKEMIA]. , 1964, Orvosi Hetilap.
[4] E. Csanyi. The absorption of 1,6-dibromo-1,6-didesoxy-d-mannitol in normal and in tumour-bearing rats. , 1967, Arzneimittel-Forschung.
[5] V. Ujházy,et al. Clinical application of myelobromol in chronic myeloses. , 1966, Neoplasma.
[6] H. Gerhartz,et al. Die Chemotherapie Leukämiekranker mit Myelobromol , 1965 .
[7] L. Institóris,et al. [ON THE EFFECT OF GLUCOSE ON THE TOXIC AND THERAPEUTIC EFFECTS OF 1,6-DIBROMO-1,6-D-DIDESOXYMANNITOL IN ANIMAL EXPERIMENTS]. , 1964, Neoplasma (Bratislava).
[8] L. Institóris,et al. STUDY ON THE DISTRIBUTION AND METABOLISM OF 82BR-LABELLED DIBROMOMANNITOL (DBM) IN NORMAL AND TUMOR-BEARING RATS. , 1964, Neoplasma.
[9] Emil Glück. Clinical Experiences with Sodium Lamp , 1942 .